Although lung cancer patients harbouring activating mutations in EGFR display initial response to TKIs targeting the activating mutation, most patients acquire resistance after a progression-free period of about 10 months due to secondary mutations in the kinase domain of EGFR [49]. Here, EGFR is linked to lung carcinoma.